INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

April 15, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List , M.D....

Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

April 15, 2021

- Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible to Receive Milestones and Royalties Based on Program Success - Precision to Host Conference Call and...

Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

April 12, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 12, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Stanley R. Frankel , M.D....

Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series

April 9, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 9, 2021-- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz , Ph.D., Chief Scientific...

Precision BioSciences Announces CEO Transition Plan

April 6, 2021

Begins Search for Next Chief Executive Officer DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today...

Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

March 29, 2021

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

March 18, 2021

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA...

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

March 12, 2021

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021....

Precision BioSciences to Present at Upcoming Virtual Investor Conferences

March 2, 2021

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced management will participate in the...

Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

February 19, 2021

Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy...

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Deck
2020 Annual Report
Investor FAQs

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal